Domain | Variable | Duloxetine | Placebo | Combined | |||
---|---|---|---|---|---|---|---|
n | r | n | r | n | r | ||
Pain | BPI average pain | 838 | 0.54 | 515 | 0.53 | 1353 | 0.55 |
SF-36 bodily pain | 794 | −0.53 | 489 | −0.56 | 1283 | −0.55 | |
FIQ pain | 820 | 0.50 | 506 | 0.51 | 1326 | 0.51 | |
FIQ stiffness | 822 | 0.45 | 506 | 0.50 | 1328 | 0.48 | |
EQ5D pain discomfort | 484 | 0.24 | 283 | 0.36 | 767 | 0.27 | |
Tender point threshold | 809 | 0.26 | 496 | 0.23 | 1305 | 0.26 | |
Physical function | BPI interference with walking | 839 | 0.43 | 515 | 0.45 | 1354 | 0.45 |
FIQ physical function | 824 | 0.39 | 505 | 0.33 | 1329 | 0.38 | |
SF-36 physical function | 794 | −0.37 | 489 | −0.33 | 1283 | −0.36 | |
EQ5D mobility | 484 | 0.25 | 283 | 0.22 | 767 | 0.24 |
BPI: Brief Pain Inventory; EQ5D: EuroQol Questionnaire 5 Dimensions; FIQ: Fibromyalgia Impact Questionnaire; MFI: Multidimensional Fatigue Inventory; SF-36: Medical Outcomes Study Short-Form 36.